Lokivetmab
Lokivetmab (Anti-Canine IL31 Recombinant Antibody) is an anti-canine IL-31 monoclonal antibody. Lokivetmab inhibits IL-31-mediated activation of pruritogenic signals in peripheral sensory neurons and reduces TH2-weighted inflammation. Lokivetmab demonstrates long-term efficacy in controlling pruritus and improving skin lesions in dogs with canine atopic dermatitis (CAD) . Lokivetmab can be used for the research of atopic dermatitis (AD) in dogs[1].
Product Specifications
CAS Number
1533403-95-0
Product Name Alternative
Anti-Canine IL31 Recombinant Antibody; CAN34D3-65; PF-06443537
UNSPSC
12352203
Target
Interleukin Related
Type
Inhibitory Antibodies
Related Pathways
Immunology/Inflammation
Applications
COVID-19-immunoregulation
Field of Research
Inflammation/Immunology
Assay Protocol
https://www.medchemexpress.com/lokivetmab.html
Purity
99.0
Solubility
H2O
Smiles
[Lokivetmab]
Molecular Weight
(147.51 kDa)
References & Citations
[1]Gober M, et al. Long term use of lokivetmab (Cytopoint®) in atopic dogs. BMC Vet Res. 2025 Mar 26;21 (1) :203.
Shipping Conditions
Dry Ice
Storage Conditions
Store at -80°C for 2 years
Scientific Category
Inhibitory Antibodies
Clinical Information
No Development Reported
Available Sizes
Frequently Asked Questions
Explore Other Products
Browse additional items from our catalog
CD63 (MX-49.129.5), CF555 conjugate, 0.1mg/mL
